 | • レポートコード：MRC2312MG09101 • 出版社/出版日：Market Monitor Global / 2023年12月 • レポート形態：英文、PDF、69ページ • 納品方法：Eメール（納期：3営業日） • 産業分類：医療 |
| Single User | ￥487,500 (USD3,250) | ▷ お問い合わせ |
| Enterprise User | ￥731,250 (USD4,875) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査レポートは次の情報を含め、世界のがんコンパニオン診断市場規模と予測を収録しています。・世界のがんコンパニオン診断市場：売上、2018年-2023年、2024年-2029年 ・世界のがんコンパニオン診断市場：販売量、2018年-2023年、2024年-2029年 ・世界のトップ5企業、2022年 世界のがんコンパニオン診断市場は2022年に000Mドルと評価され、予測期間中に000％のCAGRで2029年までに000Mドルに達すると予測されています。米国市場は2022年に000Mドルと推定されており、中国は2029年までに000Mドルに達すると予測されています。「PCR」セグメントは今後6年間、000%のCAGRで2029年までに000Mドルに成長すると予測されています。 がんコンパニオン診断のグローバル主要企業は、AmoyDx、 Novogene、 Illumina、 Roche、 Agilent、 Abbott、 Thermo Fisher、 Qiagen、 Guardant Healthなどです。2022年にトップ5企業がグローバル売上シェアの約000%を占めています。 MARKET MONITOR GLOBAL（MMG）は、がんコンパニオン診断のメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。 【セグメント別市場分析】 世界のがんコンパニオン診断市場：タイプ別、2018年-2023年、2024年-2029年 世界のがんコンパニオン診断市場：タイプ別市場シェア、2022年 ・PCR、NGS、FISH、IHC 世界のがんコンパニオン診断市場：用途別、2018年-2023年、2024年-2029年 世界のがんコンパニオン診断市場：用途別市場シェア、2022年 ・肺がん、大腸がん、乳がん、その他 世界のがんコンパニオン診断市場：地域・国別、2018年-2023年、2024年-2029年 世界のがんコンパニオン診断市場：地域別市場シェア、2022年 ・北米：アメリカ、カナダ、メキシコ ・ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア ・アジア：中国、日本、韓国、東南アジア、インド ・南米：ブラジル、アルゼンチン ・中東・アフリカ：トルコ、イスラエル、サウジアラビア、UAE 【競合分析】 また、当レポートは主要な市場参加者の分析を提供します。 ・主要企業におけるがんコンパニオン診断のグローバル売上、2018年-2023年 ・主要企業におけるがんコンパニオン診断のグローバル売上シェア、2022年 ・主要企業におけるがんコンパニオン診断のグローバル販売量、2018年-2023年 ・主要企業におけるがんコンパニオン診断のグローバル販売量シェア、2022年 さらに、当レポートは主要企業のプロファイルを提示します。 AmoyDx、 Novogene、 Illumina、 Roche、 Agilent、 Abbott、 Thermo Fisher、 Qiagen、 Guardant Health ************************************************************* ・調査・分析レポートの概要 がんコンパニオン診断市場の定義 市場セグメント 世界のがんコンパニオン診断市場概要 当レポートの特徴・ベネフィット 調査手法と情報源 ・世界のがんコンパニオン診断市場規模 世界のがんコンパニオン診断市場規模：2022年 VS 2029年 世界のがんコンパニオン診断市場規模と予測 2018年-2029年 ・競争状況 グローバルトップ企業 売上ベースでのグローバルトップ企業 企業別グローバルでのがんコンパニオン診断の売上 グローバルトップ3およびトップ5企業、2022年売上ベース グローバル企業のがんコンパニオン診断製品タイプ グローバルにおけるティア1、ティア2、ティア3企業 ・タイプ別市場分析 タイプ区分：PCR、NGS、FISH、IHC がんコンパニオン診断のタイプ別グローバル売上・予測 ・用途別市場分析 用途区分：肺がん、大腸がん、乳がん、その他 がんコンパニオン診断の用途別グローバル売上・予測 ・地域別市場分析 地域別がんコンパニオン診断市場規模 2022年と2029年 地域別がんコンパニオン診断売上・予測 北米市場：アメリカ、カナダ、メキシコ ヨーロッパ市場：ドイツ、フランス、イギリス、イタリア、ロシア アジア市場：中国、日本、韓国、東南アジア、インド 南米市場：ブラジル、アルゼンチン 中東・アフリカ市場：トルコ、イスラエル、サウジアラビア、UAE ・主要企業のプロファイル（企業概要、事業概要、主要製品、売上、ニュースなど） AmoyDx、 Novogene、 Illumina、 Roche、 Agilent、 Abbott、 Thermo Fisher、 Qiagen、 Guardant Health ... |
This research report provides a comprehensive analysis of the Cancer Companion Diagnostic market, focusing on the current trends, market dynamics, and future prospects. The report explores the global Cancer Companion Diagnostic market, including major regions such as North America, Europe, Asia-Pacific, and emerging markets. It also examines key factors driving the growth of Cancer Companion Diagnostic, challenges faced by the industry, and potential opportunities for market players.
The global Cancer Companion Diagnostic market has witnessed rapid growth in recent years, driven by increasing environmental concerns, government incentives, and advancements in technology. The Cancer Companion Diagnostic market presents opportunities for various stakeholders, including Lung Cancer, Colorectal Cancer. Collaboration between the private sector and governments can accelerate the development of supportive policies, research and development efforts, and investment in Cancer Companion Diagnostic market. Additionally, the growing consumer demand present avenues for market expansion.
The global Cancer Companion Diagnostic market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period.
The number of cancer patients is gradually increasing, drug accessibility is improving, and the research and development of targeted drugs and immunotherapy continue to increase. This is the main trend of drug development in the next ten years.
Key Features:
The research report on the Cancer Companion Diagnostic market includes several key features to provide comprehensive insights and facilitate decision-making for stakeholders.
Executive Summary: The report provides overview of the key findings, market trends, and major insights of the Cancer Companion Diagnostic market.
Market Overview: The report provides a comprehensive overview of the Cancer Companion Diagnostic market, including its definition, historical development, and current market size. It covers market segmentation by Type (e.g., Polymerase Chain Reaction (PCR), “Next Generation” Sequencing (NGS)), region, and application, highlighting the key drivers, challenges, and opportunities within each segment.
Market Dynamics: The report analyses the market dynamics driving the growth and development of the Cancer Companion Diagnostic market. The report includes an assessment of government policies and regulations, technological advancements, consumer trends and preferences, infrastructure development, and industry collaborations. This analysis helps stakeholders understand the factors influencing the Cancer Companion Diagnostic market’s trajectory.
Competitive Landscape: The report provides an in-depth analysis of the competitive landscape within the Cancer Companion Diagnostic market. It includes profiles of major market players, their market share, strategies, product portfolios, and recent developments.
Market Segmentation and Forecast: The report segment the Cancer Companion Diagnostic market based on various parameters, such as by Type, region, and by Application. It provides market size and growth forecasts for each segment, supported by quantitative data and analysis. This helps stakeholders identify growth opportunities and make informed investment decisions.
Technological Trends: The report should highlight the key technological trends shaping the Cancer Companion Diagnostic market, such as advancements in Type One technology and emerging substitutes. It analyses the impact of these trends on market growth, adoption rates, and consumer preferences.
Market Challenges and Opportunities: The report identify and analyses the major challenges faced by the Cancer Companion Diagnostic market, such as technical bottleneck, cost limitations, and high entry barrier. It also highlights the opportunities for market growth, such as government incentives, emerging markets, and collaborations between stakeholders.
Regulatory and Policy Analysis: The report should assess the regulatory and policy landscape for Cancer Companion Diagnostic, including government incentives, emission standards, and infrastructure development plans. It should analyse the impact of these policies on market growth and provide insights into future regulatory developments.
Recommendations and Conclusion: The report conclude with actionable recommendations for stakeholders, such as Application One Consumer, policymakers, investors, and infrastructure providers. These recommendations should be based on the research findings and address key challenges and opportunities within the Cancer Companion Diagnostic market.
Supporting Data and Appendices: The report include supporting data, charts, and graphs to substantiate the analysis and findings. It also includes appendices with additional detailed information, such as data sources, survey questionnaires, and detailed market forecasts.
Market Segmentation
Cancer Companion Diagnostic market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Market segment by Type
Polymerase Chain Reaction (PCR)
“Next Generation” Sequencing (NGS)
Fluorescence In Situ Hybridization (FISH)
Immunohistochemistry (IHC)
Market segment by Application
Lung Cancer
Colorectal Cancer
Breast Cancer
Others
Global Cancer Companion Diagnostic Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Major players covered
AmoyDx
Novogene
Illumina
Roche
Agilent
Abbott
Thermo Fisher
Qiagen
Guardant Health
Outline of Major Chapters:
Chapter 1: Introduces the definition of Cancer Companion Diagnostic, market overview.
Chapter 2: Global Cancer Companion Diagnostic market size in revenue.
Chapter 3: Detailed analysis of Cancer Companion Diagnostic company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Cancer Companion Diagnostic in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
1 Introduction to Research & Analysis Reports
1.1 Cancer Companion Diagnostic Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Cancer Companion Diagnostic Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Cancer Companion Diagnostic Overall Market Size
2.1 Global Cancer Companion Diagnostic Market Size: 2022 VS 2029
2.2 Global Cancer Companion Diagnostic Market Size, Prospects & Forecasts: 2018-2029
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Cancer Companion Diagnostic Players in Global Market
3.2 Top Global Cancer Companion Diagnostic Companies Ranked by Revenue
3.3 Global Cancer Companion Diagnostic Revenue by Companies
3.4 Top 3 and Top 5 Cancer Companion Diagnostic Companies in Global Market, by Revenue in 2022
3.5 Global Companies Cancer Companion Diagnostic Product Type
3.6 Tier 1, Tier 2 and Tier 3 Cancer Companion Diagnostic Players in Global Market
3.6.1 List of Global Tier 1 Cancer Companion Diagnostic Companies
3.6.2 List of Global Tier 2 and Tier 3 Cancer Companion Diagnostic Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type – Global Cancer Companion Diagnostic Market Size Markets, 2022 & 2029
4.1.2 Polymerase Chain Reaction (PCR)
4.1.3 “Next Generation” Sequencing (NGS)
4.1.4 Fluorescence In Situ Hybridization (FISH)
4.1.5 Immunohistochemistry (IHC)
4.2 By Type – Global Cancer Companion Diagnostic Revenue & Forecasts
4.2.1 By Type – Global Cancer Companion Diagnostic Revenue, 2018-2023
4.2.2 By Type – Global Cancer Companion Diagnostic Revenue, 2024-2029
4.2.3 By Type – Global Cancer Companion Diagnostic Revenue Market Share, 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global Cancer Companion Diagnostic Market Size, 2022 & 2029
5.1.2 Lung Cancer
5.1.3 Colorectal Cancer
5.1.4 Breast Cancer
5.1.5 Others
5.2 By Application – Global Cancer Companion Diagnostic Revenue & Forecasts
5.2.1 By Application – Global Cancer Companion Diagnostic Revenue, 2018-2023
5.2.2 By Application – Global Cancer Companion Diagnostic Revenue, 2024-2029
5.2.3 By Application – Global Cancer Companion Diagnostic Revenue Market Share, 2018-2029
6 Sights by Region
6.1 By Region – Global Cancer Companion Diagnostic Market Size, 2022 & 2029
6.2 By Region – Global Cancer Companion Diagnostic Revenue & Forecasts
6.2.1 By Region – Global Cancer Companion Diagnostic Revenue, 2018-2023
6.2.2 By Region – Global Cancer Companion Diagnostic Revenue, 2024-2029
6.2.3 By Region – Global Cancer Companion Diagnostic Revenue Market Share, 2018-2029
6.3 North America
6.3.1 By Country – North America Cancer Companion Diagnostic Revenue, 2018-2029
6.3.2 US Cancer Companion Diagnostic Market Size, 2018-2029
6.3.3 Canada Cancer Companion Diagnostic Market Size, 2018-2029
6.3.4 Mexico Cancer Companion Diagnostic Market Size, 2018-2029
6.4 Europe
6.4.1 By Country – Europe Cancer Companion Diagnostic Revenue, 2018-2029
6.4.2 Germany Cancer Companion Diagnostic Market Size, 2018-2029
6.4.3 France Cancer Companion Diagnostic Market Size, 2018-2029
6.4.4 U.K. Cancer Companion Diagnostic Market Size, 2018-2029
6.4.5 Italy Cancer Companion Diagnostic Market Size, 2018-2029
6.4.6 Russia Cancer Companion Diagnostic Market Size, 2018-2029
6.4.7 Nordic Countries Cancer Companion Diagnostic Market Size, 2018-2029
6.4.8 Benelux Cancer Companion Diagnostic Market Size, 2018-2029
6.5 Asia
6.5.1 By Region – Asia Cancer Companion Diagnostic Revenue, 2018-2029
6.5.2 China Cancer Companion Diagnostic Market Size, 2018-2029
6.5.3 Japan Cancer Companion Diagnostic Market Size, 2018-2029
6.5.4 South Korea Cancer Companion Diagnostic Market Size, 2018-2029
6.5.5 Southeast Asia Cancer Companion Diagnostic Market Size, 2018-2029
6.5.6 India Cancer Companion Diagnostic Market Size, 2018-2029
6.6 South America
6.6.1 By Country – South America Cancer Companion Diagnostic Revenue, 2018-2029
6.6.2 Brazil Cancer Companion Diagnostic Market Size, 2018-2029
6.6.3 Argentina Cancer Companion Diagnostic Market Size, 2018-2029
6.7 Middle East & Africa
6.7.1 By Country – Middle East & Africa Cancer Companion Diagnostic Revenue, 2018-2029
6.7.2 Turkey Cancer Companion Diagnostic Market Size, 2018-2029
6.7.3 Israel Cancer Companion Diagnostic Market Size, 2018-2029
6.7.4 Saudi Arabia Cancer Companion Diagnostic Market Size, 2018-2029
6.7.5 UAE Cancer Companion Diagnostic Market Size, 2018-2029
7 Cancer Companion Diagnostic Companies Profiles
7.1 AmoyDx
7.1.1 AmoyDx Company Summary
7.1.2 AmoyDx Business Overview
7.1.3 AmoyDx Cancer Companion Diagnostic Major Product Offerings
7.1.4 AmoyDx Cancer Companion Diagnostic Revenue in Global Market (2018-2023)
7.1.5 AmoyDx Key News & Latest Developments
7.2 Novogene
7.2.1 Novogene Company Summary
7.2.2 Novogene Business Overview
7.2.3 Novogene Cancer Companion Diagnostic Major Product Offerings
7.2.4 Novogene Cancer Companion Diagnostic Revenue in Global Market (2018-2023)
7.2.5 Novogene Key News & Latest Developments
7.3 Illumina
7.3.1 Illumina Company Summary
7.3.2 Illumina Business Overview
7.3.3 Illumina Cancer Companion Diagnostic Major Product Offerings
7.3.4 Illumina Cancer Companion Diagnostic Revenue in Global Market (2018-2023)
7.3.5 Illumina Key News & Latest Developments
7.4 Roche
7.4.1 Roche Company Summary
7.4.2 Roche Business Overview
7.4.3 Roche Cancer Companion Diagnostic Major Product Offerings
7.4.4 Roche Cancer Companion Diagnostic Revenue in Global Market (2018-2023)
7.4.5 Roche Key News & Latest Developments
7.5 Agilent
7.5.1 Agilent Company Summary
7.5.2 Agilent Business Overview
7.5.3 Agilent Cancer Companion Diagnostic Major Product Offerings
7.5.4 Agilent Cancer Companion Diagnostic Revenue in Global Market (2018-2023)
7.5.5 Agilent Key News & Latest Developments
7.6 Abbott
7.6.1 Abbott Company Summary
7.6.2 Abbott Business Overview
7.6.3 Abbott Cancer Companion Diagnostic Major Product Offerings
7.6.4 Abbott Cancer Companion Diagnostic Revenue in Global Market (2018-2023)
7.6.5 Abbott Key News & Latest Developments
7.7 Thermo Fisher
7.7.1 Thermo Fisher Company Summary
7.7.2 Thermo Fisher Business Overview
7.7.3 Thermo Fisher Cancer Companion Diagnostic Major Product Offerings
7.7.4 Thermo Fisher Cancer Companion Diagnostic Revenue in Global Market (2018-2023)
7.7.5 Thermo Fisher Key News & Latest Developments
7.8 Qiagen
7.8.1 Qiagen Company Summary
7.8.2 Qiagen Business Overview
7.8.3 Qiagen Cancer Companion Diagnostic Major Product Offerings
7.8.4 Qiagen Cancer Companion Diagnostic Revenue in Global Market (2018-2023)
7.8.5 Qiagen Key News & Latest Developments
7.9 Guardant Health
7.9.1 Guardant Health Company Summary
7.9.2 Guardant Health Business Overview
7.9.3 Guardant Health Cancer Companion Diagnostic Major Product Offerings
7.9.4 Guardant Health Cancer Companion Diagnostic Revenue in Global Market (2018-2023)
7.9.5 Guardant Health Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
